Read Gene

Read Gene EPS Growth

The EPS Growth of Read Gene (RDG.WA) as of Nov 6, 2026 is 108.72 %. In the previous year, EPS Growth was 17.49 % — a change of 521.61% (higher).

EPS Growth

108.72 %

YoY

521.61%

Last updated:

EPS Growth of Read Gene is 2025 108.72 % . EPS Growth of Read Gene was 2024 17.49 % . It decreases by 521.61% higher compared to the previous year.

The Read Gene EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
2,203.69 PLN
Jan 1, 2019
-110.56 PLN
Jan 1, 2020
420.74 PLN
Jan 1, 2021
12,161.80 PLN
Jan 1, 2022
458.09 PLN
Jan 1, 2023
-100.64 PLN
Jan 1, 2024
17.49 PLN
Jan 1, 2025
108.72 PLN
The Read Gene EPS Growth history
YEAREPS GrowthYoY
108.72 %+521.61%
17.49 %-117.38%
-100.64 %-121.97%
458.09 %-96.23%
12,161.80 %+2,790.60%
420.74 %-480.54%
-110.56 %-105.02%
2,203.69 %+2,315.51%
91.23 %+237.44%
27.04 %+50.36%
17.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

EPS Growth of Read Gene is 108.72 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Read Gene since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Read Gene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Read Gene

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Read Gene